Catalyst
Slingshot members are tracking this event:
Allergan (AGN) Announces FDA Approval Of RHOFADE (Oxymetazoline Hydrochloride) Cream, 1% For The Topical Treatment Of Persistent Facial Erythema Associated With Rosacea In Adults
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 19, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rhofade, Oxymetazoline Hydrochloride, Persistent Facial Erythema, Rosacea
